Does this include injectable Wegovy?
No. This series follows the Wegovy pill product. Keeping oral and injectable sales separate helps show how each contributes to obesity-care revenue.
Issuer definitionHistorical operating KPI
Novo Nordisk Wegovy Pill Revenue
- Latest reported
- 3.22B DKK
- Period
- Q2 2026
- QoQ
- +42.6%
- YoY
- —
Quarterly history chart
Novo Nordisk Wegovy Pill Revenue has 2 quarterly observations through Q2 2026. Bars show normalized relative relationships, not historical raw values. Complete values are available through the VizualStocks API.
Understanding Wegovy Pill Revenue
Why does Wegovy pill have a short history?
The pill launched in 2026, so the quarterly series begins with its commercial launch. Values are shown in Danish kroner, matching Novo Nordisk’s reporting currency.